Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 15;52(2):171-7.
doi: 10.3325/cmj.2011.52.171.

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study

Bozica Matković  1 , Antonio Juretić, Giulio C Spagnoli, Viktor Separović, Marija Gamulin, Robert Separović, Nera Sarić, Martina Basić-Koretić, Irena Novosel, Bozo Kruslin
Affiliations

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study

Bozica Matković et al. Croat Med J. .

Abstract

Aim: To immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis (C/T) tumor antigens in medullary breast cancer (MBC) tumor samples and to analyze it in relation to the clinicopathological features.

Methods: This retrospective study included samples from 49 patients: 40 with typical MBC and 9 with atypical MBC. Tumor specimens were obtained from patients operated on in the University Hospital for Tumors and the Sisters of Mercy University Hospital, Zagreb, Croatia, from 1999 to 2005. Standard immunohistochemistry was used on archival paraffin-embedded MBC tissues.

Results: MAGE-A1, MAGE-A, and NY-ESO-1 antigens were expressed in 33% (16/49), 33% (16/49), and 22% (11/49) of patients, respectively. No difference between the groups with and without C/T tumor antigen expression in age at diagnosis, tumor size, axillary lymph node metastasis, adjuvant therapy, and HER-2 expression was identified. Significantly more patients died in the MAGE-A-positive group than in the MAGE-A-negative group (P=0.010), whereas a borderline significance was found between MAGE-A1-positive and the MAGE-A1-negative group (P=0.079) and between NY-ESO-1-positive and NY-ESO-1-negative group (P=0.117). Overall survival, as evaluated by the Kaplan-Meier curves, was lower in MAGE-A1- (P=0.031), MAGE-A- (P=0.004), NY-ESO-1-positive groups (P=0.077).

Conclusion: Expression of C/T antigens may represent a marker of potential prognostic relevance in MBC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunohistochemical staining of MAGE-A1 and MAGE-A in medullary breast cancer tissues. (A) MAGE-A1 positive staining by monoclonal antibody 77B (PAP 40 × ). (B) MAGE-A positive staining by monoclonal antibody 57B (PAP 200 × ).
Figure 2
Figure 2
Kaplan-Meier survival curves of the expression of MAGE-A1, log rank test; P = 0.031 (A), MAGE-A, log rank test; P = 0.004 (B), and NY-ESO-1, log rank test; P = 0.077 (C) in medullary breast cancer tissues. Closed circle – dead patients; open circle – alive patients; full line – negative expression; interrupted line – positive expression.
See this image and copyright information in PMC

References

    1. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B. The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia. 2000;5:139–63. doi: 10.1023/A:1026439204849. - DOI - PubMed
    1. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009;59:303–13. doi: 10.3322/caac.20029. - DOI - PubMed
    1. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117:3155–63. doi: 10.1172/JCI33295. - DOI - PMC - PubMed
    1. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718–30. doi: 10.1038/nrclinonc.2009.166. - DOI - PubMed
    1. Bosch A, Eroles P, Zaragoza R, Vińa JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206–15. doi: 10.1016/j.ctrv.2009.12.002. - DOI - PubMed

Publication types

MeSH terms